1. (Withdrawn-currently amended) A method for enhancing fibroblast migration at a wound site comprising:

contacting the wound site with a fibrinogen preparation comprising a composition according to claim 9~~, wherein the fibrinogen preparation includes a lipid rich component~~.

2. (Withdrawn) A method according to claim 1 wherein the fibrinogen preparation further comprises fibrinogen prepared by a process which comprises precipitating plasma with glycine.

3. (Withdrawn) A method according to claim 2 wherein the fibrinogen preparation further comprises a growth factor, an extracellular matrix material, or mixtures thereof.

4. (Withdrawn) A method according to claim 2 wherein the precipitating is carried out by a process which comprises:

adding glycine to plasma to produce a precipitate and a supernatant;

dissolving the precipitate in a buffer to produce a solution; and

precipitating the solution by adding glycine to the solution.

5. (Withdrawn) A method according to claim 2 wherein the fibrinogen in prepared by a process comprising:

precipitating plasma with glycine to produce a first precipitate and a first supernatant;

dissolving the first precipitate in a buffer to produce a first solution;

precipitating the first solution by adding glycine to the first solution to produce a second precipitate and a second supernatant;

dissolving the second precipitate in a buffer to

produce a second solution; and

precipitating the second solution by adding ammonium sulfate to the second solution to produce a third precipitate and a third supernatant.

6. (Withdrawn) A method according to claim 5 wherein the third supernatant comprises a lipid rich layer.

7. (Withdrawn) A method according to claim 6 wherein the third supernatant is further treated to produce the lipid rich component.

8. (Withdrawn) A method according to claim 7 wherein the third supernatant is precipitated to produce the lipid rich component.

9. (Original) A composition comprising:
a lipid rich component and
fibrinogen.

10. (Original) A composition according to claim 9 wherein the fibrinogen has a purity of above 95%.

11. (Original) A composition according to claim 9 wherein the fibrinogen has a purity of about 99%.

12. (Original) A composition according to claim 9 wherein the fibrinogen is prepared by a process which comprises precipitating plasma with glycine.

13. (Original) A composition according to claim 12 wherein the fibrinogen is prepared by a process which comprises:

precipitating plasma with glycine to produce a first precipitate and a first supernatant;

dissolving the first precipitate in a buffer to

produce a first solution;

precipitating the first solution by adding glycine to the first solution to produce a second precipitate and a second supernatant;

dissolving the second precipitate in a buffer to produce a second solution; and

precipitating the second solution by adding ammonium sulfate to the second solution to produce a third precipitate and a third supernatant.

14. (Original) A composition according to claim 9 wherein the lipid rich component is prepared by a process which comprises precipitating plasma with glycine.

15. (Original) A composition according to claim 14 wherein the lipid rich component is prepared by a process which comprises:

precipitating plasma with glycine to produce a first precipitate and a first supernatant;

dissolving the first precipitate in a buffer to produce a first solution;

precipitating the first solution by adding glycine to the first solution to produce a second precipitate and a second supernatant;

dissolving the second precipitate in a buffer to produce a second solution;

precipitating the second solution by adding ammonium sulfate to the second solution to produce a third precipitate and a third supernatant; and

precipitating the third supernatant to produce the lipid rich component.

Respectfully submitted,

July 28, 2005
Date

Karla M. Weyand
Reg. No. 40,223

Rogalskyj & Weyand, LLP
P.O. Box 44
Livonia, New York 14487-0044
Tel: 716-625-5380
Fax: 716-626-5384

I hereby certify that this document is being deposited with the U.S. Postal Service as first class mail on 7/28/05 under 37 CFR 1.8 and is addressed to the Commissioner for Patent, PO Box 1450, Alexandria, VA 22313-1450

Signature of Person Mailing Correspondence

Karla M. Weyand
Typed Name of Person Mailing Correspondence

I:\001\00254\B6